Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Vet Pathol ; 53(6): 1264-1265, 2016 11.
Article in English | MEDLINE | ID: mdl-27733703
2.
West Indian Med J ; 63(2): 179-81, 2014 Mar.
Article in English | MEDLINE | ID: mdl-25303255

ABSTRACT

OBJECTIVE: The purpose of this study was to determine if the exotic venomous species, Pterois volitans (lionfish) had reached as far south as St Vincent in the Caribbean. This predatory marine fish has successfully invaded the waters of the Western Atlantic and the Caribbean. Such success as an exotic invasive species is rare for a predatory marine fish. It is possible that the fish are growing larger and spreading faster than anticipated, thanks to a lower burden of parasites and a paucity of natural predators in their new environment. But prior to this report, no sightings of this species this far south had been reported. METHODS: The authors conducted a search along with the help of local divers and fishermen in the waters of St Vincent. RESULTS: Approximately one year after the initiation of the search, a juvenile specimen was positively confirmed and captured off the southern coast of St Vincent. CONCLUSIONS: The exotic predatory and venomous red lionfish, Pterois volitans, has successfully invaded marine waters as far south as the Windward Islands. Fishermen in these regions should be aware of this venomous species in the region and physicians must be aware of how to manage stings from such animals.

4.
Technol Cancer Res Treat ; 7(6): 433-9, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19044322

ABSTRACT

Although helical tomotherapy has been described as a means of administering accelerated partial breast irradiation, its practicality in routine whole breast irradiation as part of breast conserving therapy or chest wall irradiation has been questioned. In this technical note we describe our method of whole breast or chest wall irradiation using helical tomotherapy based image-guided, hypofractionated, simultaneous in-field boost intensity modulated radiation therapy. We have observed that excellent dose-distributions can be achieved with helical tomotherapy through a careful selection of treatment planning parameters. Dose homogeneity to the whole breast and simultaneously targeted lumpectomy region appears superior to conventional "tangents" with minimal hot or cold spots. Dose-volume histogram analysis documents effective reduction of high dose to critical sensitive structures (heart and lung) although a greater volume of these non-target organs receives low dose compared to what is typical with tangential beams. Treatment planning is efficient and is usually completed within one to two hours, although physician contouring requires more time and attention than non-IMRT approaches. Pretreatment megavoltage CT (MVCT) imaging has proved invaluable in aiding set-up and engenders greater confidence that the planned IMRT dose distributions are truly being delivered. In some situations, MVCT can provide visual feedback when a seroma or overall breast volume has changed significantly since simulation, thereby identifying cases where replanning might be prudent. Treatment is brief, typically completed in 6 to 9 minutes. Initial clinical application has confirmed the feasibility and practicality of helical tomotherapy as an efficient means of administering radiation therapy for routine breast-conserving therapy and post-mastectomy chest wall irradiation. A simultaneous in-field boost technique reduces the length of the overall course by about a week thereby adding convenience and reducing costs. Further refinements of our technique are being explored and formal prospective clinical evaluation is underway.


Subject(s)
Breast Neoplasms/radiotherapy , Dose Fractionation, Radiation , Radiotherapy, Intensity-Modulated/methods , Breast/radiation effects , Computer Simulation , Dose-Response Relationship, Radiation , Female , Humans , Imaging, Three-Dimensional , Radiometry , Radiotherapy Planning, Computer-Assisted/methods , Reproducibility of Results , Thoracic Wall/diagnostic imaging , Time Factors , Tomography, X-Ray Computed/methods
6.
Br J Dermatol ; 152(4): 777-9, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15840113

ABSTRACT

BACKGROUND: Dissecting cellulitis of the scalp can be an extremely painful and disfiguring dermatological condition. The associated pain can be severe enough in some cases to require opioid analgesics, and this pain in conjunction with the disfigurement can induce significant emotional distress. Conservative treatments often fail to provide relief. Radiation therapy has been successfully used in the past but with outdated equipment and techniques. OBJECTIVES: To evaluate the efficacy and toxicity of modern external beam radiation therapy techniques for the treatment of dissecting cellulitis of the scalp. METHODS: Four patients with intractable dissecting cellulitis of the scalp were treated with electrons or a combination of electrons and photons to the entire scalp. Daily fraction sizes were 2.5 or 3 Gy and initially prescribed to 15-21 Gy. Patients were re-evaluated 3-4 weeks after completion of therapy. Any residual hair growth was treated with additional radiation treatments to ensure full epilation, up to a maximum dose of 35 Gy. RESULTS: Rapid resolution of pain was seen in all patients with pain. Regression of nodules and decreased discharge was seen in all patients following treatment and cosmesis was subjectively improved. No long-term toxicity has been observed. CONCLUSIONS: Using modern techniques and equipment, radiation therapy appears to be a reasonable option for patients with severe/refractory dissecting cellulitis of the scalp. Acute effects are mild and well tolerated. Aside from alopecia, which was present to some extent in all patients before treatment, no long-term complications have been observed.


Subject(s)
Cellulitis/radiotherapy , Scalp Dermatoses/radiotherapy , Adult , Cellulitis/complications , Humans , Male , Pain/etiology , Pain/radiotherapy , Radiotherapy/adverse effects , Scalp Dermatoses/complications , Treatment Outcome
7.
Int J Radiat Oncol Biol Phys ; 57(1): 166-71, 2003 Sep 01.
Article in English | MEDLINE | ID: mdl-12909229

ABSTRACT

PURPOSE: In patients in whom bone marrow transplantation (BMT) fails, recurrence often occurs at sites known to have contained disease before initiating BMT. The purpose of this study was to find the maximal tolerable dose of locoregional irradiation (LRT) between 1000 and 2000 cGy that could be integrated with our Cytoxan-total body irradiation (TBI) BMT conditioning regimen in the treatment of lymphoma. METHODS AND MATERIALS: Patients had Hodgkin's or non-Hodgkin's lymphoma in chemotherapy-refractory relapse. All patients received LRT to a maximum of three sets of fields encompassing either all current or all previously known sites of disease. Cytoxan-TBI consisted of cyclophosphamide 50 mg/kg daily for 4 days followed by TBI of 1200 cGy given in four fractions. RESULTS: Twenty-one patients were enrolled. Radiation Therapy Oncology Group Grade 3 in-field acute toxicity was observed in 1 patient at each dose level up to 1500 cGy and in 3 of 6 patients receiving 2000 cGy. Clinically evident late toxicities were limited to hypothyroidism and one second malignancy occurring outside the LRT fields. CONCLUSION: Low-dose-rate, LRT with concurrent Cytoxan-TBI before BMT has acceptable rates of in-field toxicity for doses up to 1500 cGy in five fractions. This regimen safely permits the use of a total combined radiation dose of up to 2700 cGy during 2 weeks, with encouraging in-field response rates in treatment-refractory patients.


Subject(s)
Cyclophosphamide/therapeutic use , Hodgkin Disease/drug therapy , Hodgkin Disease/radiotherapy , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/radiotherapy , Maximum Tolerated Dose , Whole-Body Irradiation/methods , Adolescent , Adult , Aged , Bone Marrow Transplantation , Combined Modality Therapy/adverse effects , Combined Modality Therapy/methods , Dose-Response Relationship, Radiation , Hodgkin Disease/mortality , Hodgkin Disease/therapy , Humans , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/therapy , Middle Aged , Radiotherapy Dosage , Treatment Outcome , Whole-Body Irradiation/adverse effects
8.
Int J Radiat Oncol Biol Phys ; 51(2): 455-9, 2001 Oct 01.
Article in English | MEDLINE | ID: mdl-11567821

ABSTRACT

PURPOSE: To evaluate the incidence of gastrointestinal complications in patients with inflammatory bowel disease (IBD) receiving radiotherapy (RT) and to identify possibly avoidable factors associated with these complications. METHODS AND MATERIALS: Twenty-four patients were identified and their records reviewed; all had a history of IBD before receiving RT to fields encompassing some portion of the gastrointestinal tract (Crohn's disease) or to the abdomen or pelvis (ulcerative colitis or IBD not otherwise specified). RESULTS: Five of 24 patients (21%) experienced Grade > or =3 acute gastrointestinal toxicity; all 5 received concurrent chemotherapy. Two of 24 patients (8%) experienced Grade > or =3 late gastrointestinal toxicity. There were no significant correlations between complications and IBD type, prior IBD-related surgery, use of medications for IBD, or status of IBD. CONCLUSION: Patients with IBD may have an increased risk for severe acute RT-related gastrointestinal complications that is more modest than generally perceived, because all patients who had Grade > or =3 acute complications in this study had received concurrent chemotherapy (p = 0.04). Further study is needed to assess this risk, as well as the impact of RT on these patients' future gastrointestinal morbidity.


Subject(s)
Colitis, Ulcerative/complications , Crohn Disease/complications , Gastrointestinal Diseases/etiology , Radiation Injuries/etiology , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Combined Modality Therapy/adverse effects , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pelvis , Radiotherapy Dosage , Retrospective Studies , Time Factors , Whole-Body Irradiation/adverse effects
13.
Clin Nucl Med ; 24(1): 54-6, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9890495

ABSTRACT

PURPOSE: This report illustrates the utility of ventilation-perfusion scintigraphy in differentiating radiation pneumonitis from other causes of dyspnea, including pulmonary embolism, heart failure, obstructive tumor, and chronic obstructive pulmonary disease. METHODS AND RESULTS: A nonsegmental mismatched perfusion abnormality, which exactly conformed to a radiation port, was diagnostic of radiation pneumonitis. CONCLUSION: In patients with lung tumors presenting with dyspnea, ventilation-perfusion scintigraphy may be useful in diagnosing radiation pneumonitis and effectively excluding other causes of dyspnea.


Subject(s)
Radiation Pneumonitis/diagnostic imaging , Radiopharmaceuticals , Technetium Tc 99m Aggregated Albumin , Ventilation-Perfusion Ratio , Carcinoma, Non-Small-Cell Lung/radiotherapy , Diagnosis, Differential , Female , Humans , Lung/diagnostic imaging , Lung/radiation effects , Lung Neoplasms/radiotherapy , Middle Aged , Pulmonary Embolism/diagnostic imaging , Radionuclide Imaging
14.
Am Pharm ; NS20(11): 25, 1980 Nov.
Article in English | MEDLINE | ID: mdl-7457344
15.
Am Pharm ; NS20(11): 30-1, 1980 Nov.
Article in English | MEDLINE | ID: mdl-7457345
18.
SELECTION OF CITATIONS
SEARCH DETAIL